Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity

Hearing Research

Volumn 299, Issue , 2013, Pages 37-45

  Waissbluth, Sofia ^a   Daniel, Sam J ^a,b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CASPASE INHIBITOR; CHLORIDE CHANNEL; CISPLATIN; COPPER; DNA; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC CATION TRANSPORTER; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CANCER SURVIVOR; CISPLATIN INDUCED OTOTOXICITY; DNA BINDING; DRUG INDUCED DISEASE; DRUG POTENCY; HUMAN; INNER EAR; MECHANOTRANSDUCTION; OTOTOXICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CISPLATIN; COCHLEA; CYTOPROTECTION; HEARING LOSS, SENSORINEURAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; PROTECTIVE AGENTS;

EID: 84875271492     PISSN: 03785955     EISSN: 18785891     Source Type: Journal    
DOI: 10.1016/j.heares.2013.02.002     Document Type: Review

References (154)

1. Agopyan N., Head J., Yu S., Simon S.A. TRPV1 receptors mediate particulate matter-induced apoptosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L563-L572.
2. Alharazneh A., Luk L., Huth M., Monfared A., Steyge r P.S., Cheng A.G., Ricci A.J. Functional hair cell mechanotransducer channels are required for aminoglycoside ototoxicity. PLoS One 2011, 6:e22347.
3. Altenberg G.A. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr. Med. Chem. Anticancer Agents 2004, 4:53-62.
4. Anderson M.E., Naganuma A., Mesiter A. Protection against cisplatin toxicity by administration of glutathione ester. FASEB J. 1990, 4:3251-3255.
5. Banci L., Bertini I., Cantini F., Ciofi-Baffoni S. Cellular copper distribution: a mechanistic systems biology approach. Cell. Mol. Life Sci. 2010, 67:2563-2589.
6. Banci L., Bertini I., Blazevits O., Calderone V., Cantini F., Mao J., Trapananti A., Vieru M., Amori I., Cozzolino M., Carri M.T. Interaction of cisplatin with human superoxide dismutase. J. Am. Chem. Soc. 2012, 134:7009-7014.
7. Barnes P.J. Nuclear factor-kappa B. Int. J. Biochem. Cell. Biol. 1997, 29:867-870.
8. Belinsky M.G., Chen Z.S., Shchaveleva I., Zeng H., Kruh G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002, 62:6172-6177.
9. Beretta G.L., Gatti L., Tinelli S., Corna E., Colangelo D., Zunino F., Perego P. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem. Pharmacol. 2004, 68:283-291.
10. Blair B.G., Larson C.A., Adams P.L., Abada P.B., Pesce C.E., Safaei R., Howell S.B. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol. Pharmacol. 2011, 79:157-166.
11. Blair B.G., Larson C.A., Adams P.L., Abada P.B., Safaei R., Howell S.B. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2010, 77:912-921.
12. Blair B.G., Larson C.A., Safaei R., Howell S.B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res. 2009, 15:4312-4321.
13. Block K.I., Koch A.C., Mead M.N., Tothy P.K., Newman R.A., Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat. Rev. 2007, 33:407-418.
14. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92:1295-1302.
15. Broker L.E., Kruyt F.A., Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 2005, 11:3155-3162.
16. Budiman T., Bamberg E., Koepsell H., Nagel G. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J. Biol. Chem. 2000, 275:29413-29420.
17. Campbell K.C., Meech R.P., Klemens J.J., Gerberi M.T., Dyrstad S.S., Larsen D.L., Mitchell D.L., El-Azizi M., Verhulst S.J., Hughes L.F. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear. Res. 2007, 226:92-103.
18. Castiglioni A.J., Remis N.N., Flores E.N., García-Añoveros J. Expression and vesicular localization of mouse Trpml3 in stria vascularis, hair cells, and vomeronasal and olfactory receptor neurons. J. Comp. Neurol. 2011, 519:1095-1114.
19. Chen W.C., Xue H.Z., Hsu Y.L., Liu Q., Patel S., Davis R.L. Complex distribution patterns of voltage-gated calcium channel alpha-subunits in the spiral ganglion. Hear. Res. 2011, 278:52-68.
20. Choe W.T., Chinosornvatana N., Chang K.W. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol. 2004, 25:910-915.
21. Choi M.K., Kim D.D. Platinum transporters and drug resistance. Arch. Pharm. Res. 2006, 29:1067-1073.
22. Chung W.H., Boo S.H., Chung M.K., Lee H.S., Cho Y.S., Hong S.H. Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol. 2008, 128:1063-1070.
23. Ciarimboli G. Role of organic cation transporters in drug-induced toxicity. Expert Opin. Drug Metab. Toxicol. 2011, 7:159-174.
24. Ciarimboli G., Deuster D., Knief A., Sperling M., Holtkamp M., Edemir B., Pavenstädt H., Lanvers-Kaminsky C., am Zehnhoff-Dinnesen A., Schinkel A.H., Koepsell H., Jürgens H., Schlatter E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176:1169-1180.
25. Ciarimboli G., Ludwig T., Lang D., Pavenstädt H., Koepsell H., Piechota H.J., Haier J., Jaehde U., Zisowsky J., Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167:1477-1484.
26. Clapham D.E., Julius D., Montell C., Schultz G. International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels. Pharmacol. Rev. 2005, 57:427-450.
27. Cooper L.B., Chan D.K., Roediger F.C., Shaffer B.R., Fraser J.F., Musatov S., Selesnick S.H., Kaplitt M.G. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol Neurotol. 2006, 27:484-490.
28. Corey D.P., García-Añoveros J., Holt J.R., Kwan K.Y., Lin S.Y., Vollrath M.A., Amalfitano A., Cheung E.L., Derfler B.H., Duggan A., Géléoc G.S., Gray P.A., Hoffman M.P., Rehm H.L., Tamasauskas D., Zhang D.S. TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. Nature 2004, 432:723-730.
29. Cuajungco M.P., Grimm C., Heller S. TRP channels as candidates for hearing and balance abnormalities in vertebrates. Biochim. Biophys. Acta 2007, 1772:1022-1027.
30. Cummings B.S., Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302:8-17.
31. Daldal A., Odabasi O., Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol. Head Neck Surg. 2007, 137:747-752.
32. Dean M. The Human ATP-binding Cassette (ABC) Transporter Superfamily 2002, [Internet], National Center for Biotechnology Information (US.), Bethesda (MD), Available from:. http://www.ncbi.nlm.nih.gov/books/NBK3/.
33. de Groot T., Bindels R.J., Hoenderop J.G. TRPV5: an ingeniously controlled calcium channel. Kidney Int. 2008, 74:1241-1246.
34. Deeley R.G., Westlake C., Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86:849-899.
35. Ding D., He J., Allman B.L., Yu D., Jiang H., Seigel G.M., Salvi R.J. Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear. Res. 2011, 282:196-203.
36. Farris H.E., LeBlanc C.L., Goswami J., Ricci A.J. Probing the pore of the auditory hair cell mechanotransducer channel in turtle. J. Physiol. 2004, 558:769-792.
37. Fetoni A.R., Ralli M., Sergi B., Parrilla C., Troiani D., Paludetti G. Protective effects of N-acetylcysteine on noise-induced hearing loss in guinea pigs. Acta Otorhinolaryngol. Ital 2009, 29:70-75.
38. Filipski K.K., Loos W.J., Verweij J., Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008, 14:3875-3880.
39. Frazier A.L., Weldon C., Amatruda J. Fetal and neonatal germ cell tumors. Semin. Fetal Neonatal. Med. 2012, 17:222-230.
40. Garcia-Berrocal J.R., Nevado J., Ramírez-Camacho R., Sanz R., González-García J.A., Sánchez-Rodríguez C., Cantos B., España P., Verdaguer J.M., Trinidad Cabezas A. The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br. J. Pharmacol. 2007, 152:1012-1020.
41. Giacomello M., De Mario A., Primerano S., Brini M., Carafoli E. Hair cells, plasma membrane Ca(2)(+) ATPase and deafness. Int. J. Biochem. Cell. Biol. 2012, 44:679-683.
42. Gossman D.G., Zhao H.B. Hemichannel-mediated inositol 1,4,5-trisphosphate (IP3) release in the cochlea: a novel mechanism of IP3 intercellular signaling. Cell. Commun. Adhes. 2008, 15:305-315.
43. Groschner K., Rosker C., Lukas M. Role of TRP channels in oxidative stress. Novartis Found. Symp. 2004, 258:222-230. Discussion 231-5, 263-6.
44. Hafidi A., Dulon D. Developmental expression of Ca(v)1.3 (alpha1d) calcium channels in the mouse inner ear. Brain Res. Dev. Brain Res. 2004, 150:167-175.
45. Haimeur A., Conseil G., Deeley R.G., Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 2004, 5:21-53.
46. Hajnoczky G., Csordás G., Madesh M., Pacher P. Control of apoptosis by IP(3) and ryanodine receptor driven calcium signals. Cell Calcium 2000, 28:349-363.
47. Hartmann J.T., Lipp H.P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4:889-901.
48. Hill G.W., Morest D.K., Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol. 2008, 29:1005-1011.
49. Holzer A.K., Samimi G., Katano K., Naerdemann W., Lin X., Safaei R., Howell S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004, 66:817-823.
50. Homma K., Miller K.K., Anderson C.T., Sengupta S., Du G.G., Aguiñaga S., Cheatham M., Dallos P., Zheng J. Interaction between CFTR and prestin (SLC26A5). Biochim. Biophys. Acta 2010, 1798:1029-1040.
51. Howell S.B., Safaei R. CTR1 as a determinant of platinum drug transport. Platinum Other Heavy Metal Compounds Cancer Chemother. 2009, 2:89-94.
52. Howell S.B., Safaei R., Larson C.A., Sailor M.J. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol. Pharmacol. 2010, 77:887-894.
53. Huang Q., Dunn R.T., Jayadev S., DiSorbo O., Pack F.D., Farr S.B., Stoll R.E., Blanchard K.T. Assessment of cisplatin-induced nephrotoxicity. Microarray Technol. Toxicol. Sci. 2001, 63:196-207.
54. Hyppolito M.A., de Oliveira A.A., Lessa R.M., Rossato M. Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy. Braz. J. Otorhinolaryngol. 2005, 71:268-273.
55. Hyppolito M.A., de Oliveira J.A., Rossato M. Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur. Arch. Otorhinolaryngol. 2006, 263:798-803.
56. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA 2002, 99:14298-14302.
57. - channel in cisplatin-induced apoptosis in human epidermoid cancer cells. J. Membr. Biol. 2005, 205:139-145.
58. Imamura S.I., Adams J.C. Changes in cytochemistry of sensory and nonsensory cells in gentamicin-treated cochleas. JARO 2003, 4:196-218.
59. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99:2467-2498.
60. Jentsch T.J., Stein V., Weinreich F., Zdebik A.A. Molecular structure and physiological function of chloride channels. Physiol. Rev. 2002, 82:503-568.
61. Jin Y., Cai X.Y., Shi Y.X., Xia X.Y., Cai Y.C., Cao Y., Zhang W.D., Hu W.H., Jiang W.Q. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J. Cancer Res. Clin. Oncol. 2012, [published online ahead of print June 10 2012].
62. Jorgensen F., Ohmori H. Amiloride blocks the mechano-electrical transduction channel of hair cells of the chick. J. Physiol. 1988, 403:577-588.
63. Kalkanis J.G., Whitworth C., Rybak L.P. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004, 114:538-542.
64. Karasawa T., Wang Q., Fu Y., Cohen D.M., Steyger P.S. TRPV4 enhances the cellular uptake of aminoglycoside antibiotics. J. Cell. Sci. 2008, 121:2871-2879.
65. Karashima Y., Prenen J., Talavera K., Janssens A., Voets T., Nilius B. Agonist-induced changes in Ca(2+) permeation through the nociceptor cation channel TRPA1. Biophys. J. 2010, 98:773-783.
66. Karlstad J., Sun Y., Singh B.B. Ca(2+) signaling: an outlook on the characterization of ca(2+) channels and their importance in cellular functions. Adv. Exp. Med. Biol. 2012, 740:143-157.
67. Katsuda H., Yamashita M., Katsura H., Yu J., Waki Y., Nagata N., Sai Y., Miyamoto K. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol. Pharm. Bull. 2010, 33:1867-1871.
68. Kawasaki E., Hattori N., Miyamoto E., Yamashita T., Inagaki C. Single-cell RT-PCR demonstrates expression of voltage-dependent chloride channels (ClC-1, ClC-2 and ClC-3) in outer hair cells of rat cochlea. Brain Res. 1999, 838:166-170.
69. Kazmierczak P., Muller U. Sensing sound: molecules that orchestrate mechanotransduction by hair cells. Trends Neurosci. 2012, 35:220-229.
70. Kelly T.C., Whitworth C.A., Husain K., Rybak L.P. Aminoguanidine reduces cisplatin ototoxicity. Hear. Res. 2003, 186:10-16.
71. Kitada N., Takara K., Tsujimoto M., Sakaeda T., Ohnishi N., Yokoyama T. Effects of platinum derivatives on the function and expression of P-Glycoprotein/MDR1 in LLC-PK1 cells: in the cases of carboplatin and nedaplatin. J. Cancer Mol. 2007, 3:23-28.
72. Koivusalo M., Welch C., Hayashi H., Scott C.C., Kim M., Alexander T., Touret N., Hahn K.M., Grinstein S. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J. Cell. Biol. 2010, 188:547-563.
73. Kuo M.T., Chen H.H., Song I.S., Savaraj N., Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007, 26:71-83.
74. Kwan K.Y., Allchorne A.J., Vollrath M.A., Christensen A.P., Zhang D.S., Woolf C.J., Corey D.P. TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 2006, 50:277-289.
75. La Fontaine S., Mercer J.F. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch. Biochem. Biophys. 2007, 463:149-167.
76. Layton M.G., Robertson D., Everett A.W., Mulders W.H., Yates G.K. Cellular localization of voltage-gated calcium channels and synaptic vesicle-associated proteins in the guinea pig cochlea. J. Mol. Neurosci. 2005, 2:225-244.
77. Lee E.L., Shimizu T., Ise T., Numata T., Kohno K., Okada Y. Impaired activity of volume-sensitive Cl- channel is involved in cisplatin resistance of cancer cells. J. Cell. Physiol. 2007, 211:513-521.
78. Lee Y.Y., Choi C.H., Do I.G., Song S.Y., Lee W., Park H.S., Song T.J., Kim M.K., Kim T.J., Lee J.W., Bae D.S., Kim B.G. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol. Oncol. 2011, 122:361-365.
79. Lei D., Gao X., Perez P., Ohlemiller K.K., Chen C.C., Campbell K.P., Hood A.Y., Bao J. Anti-epileptic drugs delay age-related loss of spiral ganglion neurons via T-type calcium channel. Hear. Res. 2011, 278:106-112.
80. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P- glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxico Appl. Pharmacol. 2005, 204:216-237.
81. l'Hoste S., Chargui A., Belfodil R., Corcelle E., Duranton C., Rubera I., Poujeol C., Mograbi B., Tauc M., Poujeol P. CFTR mediates apoptotic volume decrease and cell death by controlling glutathione efflux and ROS production in cultured mice proximal tubules. Am. J. Physiol. Ren. Physiol. 2010, 298:F435-F453.
82. Lian H.Y., Hu M., Liu C.H., Yamauchi Y., Wu K.C. Highly biocompatible, hollow coordination polymer nanoparticles as cisplatin carriers for efficient intracellular drug delivery. Chem. Commun. (Camb) 2012, 48:5151-5153.
83. Liang Y., Huang L., Yang J. Differential expression of ryanodine receptor in the developing rat cochlea. Eur. J. Histochem. 2009, 53:249-260.
84. Lioudyno M., Hiel H., Kong J.H., Katz E., Waldman E., Parameshwaran-Iyer S., Glowatzki E., Fuchs P.A. A "synaptoplasmic cistern" mediates rapid inhibition of cochlear hair cells. J. Neurosci. 2004, 24:11160-11164.
85. Long D.F., Repta A.J. Cisplatin: chemistry, distribution and biotransformation. Biopharm. Drug Dispos. 1981, 2:1-16.
86. Lustberg M.B., Edelman M.J. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr. Treat. Options Oncol. 2007, 8:38-46.
87. Mattson M.P., Chan S.L. Calcium orchestrates apoptosis. Nat. Cell. Biol. 2003, 5:1041-1043.
88. Milosavljevic N., Duranton C., Djerbi N., Puech P.H., Gounon P., Lagadic-Gossmann D., Dimanche-Boitrel M.T., Rauch C., Tauc M., Counillon L., Poët M. Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling. Cancer Res. 2010, 70:7514-7522.
89. Min X.J., Li H., Hou S.C., He W., Liu J., Hu B., Wang J. Dysfunction of volume-sensitive chloride channels contributes to cisplatin resistance in human lung adenocarcinoma cells. Exp. Biol. Med. (Maywood) 2011, 236:483-491.
90. More S.S., Akil O., Ianculescu A.G., Geier E.G., Lustig L.R., Giacomini K.M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 2010, 30:9500-9509.
91. Morton-Jones R.T., Cannell M.B., Jeyakumar L.H., Fleischer S., Housley G.D. Differential expression of ryanodine receptors in the rat cochlea. Neuroscience 2006, 137:275-286.
92. Mukherjea D., Jajoo S., Whitworth C., Bunch J.R., Turner J.G., Rybak L.P., Ramkumar V. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J. Neurosci. 2008, 28:13056-13065.
93. Muller P.A., Klomp L.W. ATOX1: a novel copper-responsive transcription factor in mammals?. Int. J. Biochem. Cell. Biol. 2009, 41:1233-1236.
94. Murphy D., Daniel S.J. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model. Otolaryngol. Head Neck Surg. 2011, 145:452-457.
95. Muthuraman A., Singla S.K., Peters A. Exploring the potential of flunarizine for cisplatin-induced painful uremic neuropathy in rats. Int. Neurourol J. 2011, 15:127-134.
96. Nagata K., Duggan A., Kumar G., García-Añoveros J. Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. J. Neurosci. 2005, 25:4052-4061.
97. Nagata K., Zheng L., Madathany T., Castiglioni A.J., Bartles J.R., Garcia-Anoveros J. The varitint-waddler (Va) deafness mutation in TRPML3 generates constitutive, inward rectifying currents and causes cell degeneration. Proc. Natl. Acad. Sci. USA 2008, 105:353-358.
98. Nassini R., Gees M., Harrison S., De Siena G., Materazzi S., Moretto N., Failli P., Preti D., Marchetti N., Cavazzini A., Mancini F., Pedretti P., Nilius B., Patacchini R., Geppetti P. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011, 152:1621-1631.
99. Nayebi A.M., Sharifi H., Ramadzani M., Rezazadeh H. Effect of acute and chronic administration of carbamazepine on cisplatin-induced hyperalgesia in rats. Jundishapur J. Nat. Pharm. Prod. 2012, 7:27-30.
100. Nilius B., Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011, 12:218.
101. Nilius B., Owsianik G., Voets T., Peters J.A. Transient receptor potential cation channels in disease. Physiol. Rev. 2007, 87:165-217.
102. Nitiss J.L. A copper connection to the uptake of platinum anticancer drugs. Proc. Natl. Acad. Sci. USA 2002, 99:13963-13965.
103. Noben-Trauth K. The TRPML3 channel: from gene to function. Adv. Exp. Med. Biol. 2011, 704:229-237.
104. Okada Y., Shimizu T., Maeno E., Tanabe S., Wang X., Takahashi N. Volume- sensitive chloride channels involved in apoptotic volume decrease and cell death. J. Membr. Biol. 2006, 209:21-29.
105. Omura G.A. Progress in gynecologic cancer research: the gynecologic oncology group experience. Semin. Oncol. 2008, 35:507-521.
106. Oshima T., Ikeda K., Furukawa M., Takasaka T. Expression of voltage-dependent chloride channels in the rat cochlea. Hear. Res. 1997, 103:63-68.
107. Paksoy M., Ayduran E., Sanli A., Eken M., Aydin S., Oktay Z.A. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med. Oncol. 2011, 28:615-621.
108. Phan P.A., Tadros S.F., Kim Y., Birnbaumer L., Housley G.D. Developmental regulation of TRPC3 ion channel expression in the mouse cochlea. Histochem. Cell. Biol. 2010, 133:437-448.
109. Rabik C.A., Maryon E.B., Kasza K., Shafer J.T., Bartnik C.M., Dolan M.E. Role of copper transporters in resistance to platinating agents. Cancer Chemother. Pharmacol. 2009, 64:133-142.
110. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., Thigpen J.T., Benda J.A. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2006, 24:36-44. Gynecologic Oncology Group Study.
111. Rees E.M., Lee J., Thiele D.J. Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter. J. Biol. Chem. 2004, 279:54221-54229.
112. Rybak L.P., Whitworth C.A., Mukherjea D., Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear. Res. 2007, 226:157-167.
113. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 2006, 234:34-39.
114. Safaei R., Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol. 2005, 53:13-23.
115. Saito T., Zhang Z.J., Manabe Y., Ohtsubo T., Saito H. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur. Arch. Otorhinolaryngol. 1997, 254:281-286.
116. Saito T., Zhang Z.J., Tokuriki M., Ohtsubo T., Noda I., Shibamori Y., Yamamoto T., Saito H. Expression of multidrug resistance protein 1 (MRP1) in the rat cochlea with special reference to the blood-inner ear barrier. Brain Res. 2001, 895:253-257.
117. Saliba I., El Fata F., Ouelette V., Robitaille Y. Are intratympanic injections of N-acetylcysteine and methylprednisolone protective against Cisplatin-induced ototoxicity?. J. Otolaryngol. Head Neck Surg. 2010, 39:236-243.
118. Samimi G., Safaei R., Katano K., Holzer A.K., Rochdi M., Tomioka M., Goodman M., Howell S.B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10:4661-4669.
119. Schellens J.H., Planting A.S., Ma J., Maliepaard M., de Vos A., de Boer Dennert M., Verweij J. Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer Drugs 2001, 12:667-675.
120. Schmidt D., Elger C.E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav. 2004, 5:627-635.
121. Schmitt N.C., Rubel E.W., Nathanson N.M. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J. Neurosci. 2009, 29:3843-3851.
122. Sharom F.J. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem. Cell. Biol. 2006, 84:979-992.
123. Sharom F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9:105.
124. Shimizu T., Numata T., Okada Y. A role of reactive oxygen species in apoptotic activation of volume-sensitive Cl(-) channel. Proc. Natl. Acad. Sci. USA 2004, 101:6770-6773.
125. Slot A.J., Molinski S.V., Cole S.P. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011, 50:179-207.
126. So H.S., Park C., Kim H.J., Lee J.H., Park S.Y., Lee J.H., Lee Z.W., Kim H.M., Kalinec F., Lim D.J., Park R. Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear. Res. 2005, 204:127-139.
127. Song M.Y., Makino A., Yuan J.X. Role of reactive oxygen species and redox in regulating the function of transient receptor potential channels. Antioxid. Redox Signal. 2011, 15:1549-1565.
128. 2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis. Br. J. Pharmacol. 2007, 151:1176-1186.
129. Staecker H., Liu W., Malgrange B., Lefebvre P.P., Van De Water T.R. Vector-mediated delivery of bcl-2 prevents degeneration of auditory hair cells and neurons after injury. ORL J. Otorhinolaryngol. Relat. Spec. 2007, 69:43-50.
130. Stepanyan R.S., Indzhykulian A.A., Vélez-Ortega A.C., Boger E.T., Steyger P.S., Friedman T.B., Frolenkov G.I. TRPA1-mediated accumulation of aminoglycosides in mouse cochlear outer hair cells. J. Assoc. Res. Otolaryngol. 2011, 12:729-740.
131. Ta L.E., Bieber A.J., Carlton S.M., Loprinzi C.L., Low P.A., Windebank A.J. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol. Pain 2010, 6:15.
132. Tadros S.F., Kim Y., Phan P.A., Birnbaumer L., Housley G.D. TRPC3 ion channel subunit immunolocalization in the cochlea. Histochem. Cell. Biol. 2010, 133:137-147.
133. Takumida M., Kubo N., Ohtani M., Suzuka Y., Anniko M. Transient receptor potential channels in the inner ear: presence of transient receptor potential channel subfamily 1 and 4 in the guinea pig inner ear. Acta Otolaryngol. 2005, 125:929-934.
134. Takumida M., Ishibashi T., Hamamoto T., Hirakawa K., Anniko M. Age-dependent changes in the expression of klotho protein, TRPV5 and TRPV6 in mouse inner ear. Acta Otolaryngol. 2009, 129:1340-1350.
135. Takumida M., Anniko M. Expression of canonical transient receptor potential channel (TRPC) 1-7 in the mouse inner ear. Acta Otolaryngol. 2009, 129:1351-1358.
136. Takumida M., Anniko M. Expression of transient receptor potential channel mucolipin (TRPML) and polycystine (TRPP) in the mouse inner ear. Acta Otolaryngol. 2010, 130:196-203.
137. Tanida S., Mizoshita T., Ozeki K., Tsukamoto H., Kamiya T., Kataoka H., Sakamuro D., Joh T. Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int. J. Surg. Oncol. 2012, 862879.
138. Teranishi M.A., Nakashima T. Effects of trolox, locally applied on round windows, on cisplatin-induced ototoxicity in guinea pigs. Int. J. Pediatr. Otorhinolaryngol. 2003, 67:133-139.
139. Todd R.C., Lovejoy K.S., Lippard S.J. Understanding the effect of carbonate ion on cisplatin binding to DNA. J. Am. Chem. Soc. 2007, 129:6370-6371.
140. Uemaetomari I., Tabuchi K., Nakamagoe M., Tanaka S., Murashita H., Hara A. L-type voltage-gated calcium channel is involved in the pathogenesis of acoustic injury in the cochlea. Tohoku J. Exp. Med. 2009, 218:41-47.
141. Van den Berghe P.V., Folmer D.E., Malingré H.E., van Beurden E., Klomp A.E., van de Sluis B., Merkx M., Berger R., Klomp L.W. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J. 2007, 407:49-59.
142. Vilela R.M., Lands L.C., Meehan B., Kubow S. Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide. Int. Immunopharmacol. 2006, 6:1651-1664.
143. Waissbluth S., Dupuis I., Daniel S.J. Protective effect of erdosteine against cisplatin-induced ototoxicity in a guinea pig model. Otolaryngol. Head Neck Surg. 2012 Apr, 146(4):627-632.
144. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
145. Wang G.P., Xie J., Liu Y.P., Luo L.H., Lu H.T., Dong J.H., Gong S.S. Adenovirus-mediated delivery of bcl-2 gene attenuates cisplatin-induced degeneration of cultured spiral ganglion cells. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009, 44:930-934.
146. Wu L.J., Sweet T.B., Clapham D.E. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol. Rev. 2010, 62:381-404.
147. Xu Y., Zheng H., Kang J.S., Zhang L., Su J., Li H.Y., Sun L.K. 5-Nitro-2-(3-phenylpropylamino) benzoic acid induced drug resistance to cisplatin in human erythroleukemia cell lines. Anat. Rec. (Hoboken) 2011, 294:945-952.
148. Yamauchi D., Nakaya K., Raveendran N.N., Harbidge D.G., Singh R., Wangemann P., Marcus D.C. Expression of epithelial calcium transport system in rat cochlea and vestibular labyrinth. BMC Physiol. 2010, 10:1.
149. Yang X., Fraser M., Abedini M.R., Bai T., Tsang B.K. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br. J. Cancer 2008, 98:803-808.
150. Yokoo S., Yonezawa A. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 2007, 74:477-487.
151. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
152. Zhang W., Zhang C., Narayani N., Du C., Balaji K.C. Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells. Cancer Lett. 2007, 255:127-134.
153. Zoltick B.H. Shedding light on testicular cancer. Nurse Pract. 2011, 36:32-39.
154. Zorrilla de San Martin J., Ballestero J., Katz E., Elgoyhen A.B., Fuchs P.A. Ryanodine is a positive modulator of acetylcholine receptor gating in cochlear hair cells. J. Assoc. Res. Otolaryngol. 2007, 8:474-483.